Compare GSL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | SDGR |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2008 | 2020 |
| Metric | GSL | SDGR |
|---|---|---|
| Price | $43.03 | $28.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $51.00 | $33.57 |
| AVG Volume (30 Days) | 254.8K | ★ 1.7M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $4.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $32.74 | $10.95 |
| 52 Week High | $46.57 | $34.00 |
| Indicator | GSL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 54.84 |
| Support Level | $36.65 | $27.69 |
| Resistance Level | $43.26 | $32.15 |
| Average True Range (ATR) | 1.13 | 2.54 |
| MACD | 0.40 | 0.29 |
| Stochastic Oscillator | 86.93 | 55.68 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.